Immunotherapy with antidigitalis Fab fragments;Immunothérapie spécifique antidigitalique

Reanimation

Volumn 11, Issue 7, 2002, Pages 540-547

  Megarbane B ^a   Benyamina, M ^a   Baud, F ^a  

^a HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Digitoxin; Digoxin; Fab fragment; Immunotoxicotherapy; Poisoning

Indexed keywords

ANTIDOTE; ATROPINE; DESLANOSIDE; DIGITALIN; DIGITOXIN; DIGOXIN; DIGOXIN ANTIBODY F(AB) FRAGMENT; HEMIGOXINE; LANATOSIDE C;

DIGITALIS INTOXICATION; DRUG EFFECT; DRUG INDICATION; DRUG MECHANISM; DRUG USE; IMMUNOTHERAPY; MORBIDITY; MORTALITY; PRESCRIPTION; PROGNOSIS; REVIEW;

EID: 0036860419     PISSN: 16240693     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1624-0693(02)00291-8     Document Type: Short Survey

References (38)

1. Bayer MJ. Recognition and management of digitalis intoxication: Implications for emergency medicine. Am J Emerg Med 1991; 9: 29-32.
2. Kelly RA, Smith TW. Recognition and management of digitalis toxicity. Am J Cardiol 1992; 69: 108-18.
3. Mauskopf JA, Wenger TL. Cost-effectiveness analysis of the use of digoxin immune Fab (ovine) for treatment of digoxin toxicity. Am J Cardiol 1991; 68: 1709-14.
4. Hess T, Stucki P, Barandun S, Scholtysik G, Riesen W. Treatment of a case of lanatoside C intoxication with digoxin-specific F(ab′)2 antibody fragments. Am Heart J 1979; 98: 767-71.
5. Kurowski V, Iven H, Djonlagic H. Treatment of a patient with severe digitoxin intoxication by Fab fragments of anti-digitalis antibodies. Intensive Care Med 1992; 18: 439-42.
6. Shumaik GM, Wu AW, Ping AC. Oleander poisoning: Treatment with digoxin-specific Fab antibody fragments. Ann Emerg Med 1988; 17: 732-5.
7. Butler VP, Chen JP. Digoxin-specific antibodies. Proc Natl Acad Sci USA 1967; 57: 71-8.
8. Butler VP, Schmidt DH, Smith TW, Haber E, Raynor BD, Demartini P. Effects of sheep digoxin-specific antibodies and their Fab fragments on digoxin pharmacokinetics in dogs. J Clin Invest 1977; 59: 345-59.
9. Butler VP, Smith TW, Schmidt DH, Haber E. Immunological reversal of the effects of digoxin. Fed Proc 1977; 36: 2235-41.
10. Curd J, Smith TW, Jaton JC, Haber E. The isolation of digoxin-specific antibody and its use in reversing the effects of digoxin. Proc Natl Acad Sci USA 1971; 68: 2401-6.
11. Schmidt DH, Butler VP. Immunological protection against digoxin toxicity. J Clin Invest 1971; 50: 866-71.
12. Schmidt DH, Butler VP. Reversal of digoxin toxicity with specific antibodies. J Clin Invest 1971; 50: 1738-44.
13. Smith TW, Haber E, Yeatman L, Butler VP. Reversal of advanced digoxin intoxication with Fab fragments of digoxin-specific antibodies. N Engl J Med 1976; 294: 797-800.
14. Antman EM, Wenger TL, Butler VP, Haber E, Smith TW. Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments. Final report of a multicenter study. Circulation 1990; 81: 1744-52.
15. Smolarz A, Roesch E, Lenz E, Neubert H, Abshagen P. Digoxin specific antibody (Fab) fragments in 34 cases of severe digitalis intoxication. J Toxicol Clin Toxicol 1985; 23: 327-40.
16. Taboulet P, Baud FJ, Bismuth C, Vicaut E. Acute digitalis intoxication-Is pacing still appropriate? J Toxicol Clin Toxicol 1993; 31: 261-73.
17. Taboulet P, Baud FJ, Bismuth C. Clinical features and management of digitalis poisoning-Rationale for immunotherapy. J Toxicol Clin Toxicol 1993; 31: 247-60.
18. Hickey AR, Wenger TL, Carpenter VP, Tilson HH, Hlatky MA, Furberg CD, et al. Digoxin immune Fab therapy in the management of digitalis intoxication: Safety and efficacy results of an observational surveillance study. J Am Coll Cardiol 1991; 17: 590-8.
19. Bismuth C, Motte G, Conso F, Chauvin M, Gaultier M. Acute digitoxin intoxication treated by intracardiac pacemaker: Experience in sixty-eight patients. Clin Toxicol 1977; 10: 443-56.
20. Borron SW, Bismuth C, Muszynski J. Advances in the management of digoxin toxicity in the older patient. Drugs Aging 1997; 10: 18-33.
21. Baud FJ, Borron SW, Bismuth C. Modifying toxicokinetics with antidotes. Toxicol Lett 1995; 82-83: 785-93.
22. Bourhis F, Riard P, Danel V, Hostein J, Fournet J. Digitalis poisoning with severe ischemic colitis: A favorable course after treatment with specific antibodies. Gastroenterol Clin Biol 1990; 14: 95.
23. Urtizberea M, Sabouraud A, Baud F, Rochdi M, Debray M, Bismuth C, et al. Concepts for toxicokinetic-toxicodynamic modelling in clinical toxicology: Application to acute cardiac glycoside intoxications. Arch Toxicol Suppl 1992; 15: 253-6.
24. Renard C, Grene-Lerouge N, Beau N, Baud F, Scherrmann JM. Pharmacokinetics of digoxin-specific Fab: Effects of decreased renal function and age. Br J Clin Pharmacol 1997; 44: 135-8.
25. Schaumann W, Kaufmann B, Neubert P, Smolarz A. Kinetics of the Fab fragments of digoxin antibodies and of bound digoxin in patients with severe digoxin intoxication. Eur J Clin Pharmacol 1986; 30: 527-33.
26. Lloyd BL, Smith TW. Contrasting rates of reversal of digoxin toxicity by digoxin-specific IgG and Fab fragments. Circulation 1978; 58: 280-3.
27. Berkovitch M, Akilesh MR, Gerace R, Verjee Z, McGuigan M, Whyte H, et al. Acute digoxin overdose in a newborn with renal failure: Use of digoxin immune Fab and peritoneal dialysis. Ther Drug Monit 1994; 16: 531-3.
28. Gittelman MA, Stephan M, Perry H. Acute pediatric digoxin ingestion. Pediatr Emerg Care 1999; 15: 359-62.
29. Kaufman J, Leikin J, Kendzierski D, Polin K. Use of digoxin Fab immune fragments in a seven-day-old infant. Pediatr Emerg Care 1990; 6: 118-21.
30. Schmitt K, Tulzer G, Hackel F, Sommer R, Tulzer W. Massive digitoxin intoxication treated with digoxin-specific antibodies in a child. Pediatr Cardiol 1994; 15: 48-9.
31. Woolf AD, Wenger T, Smith TW, Lovejoy FH. The use of digoxin-specific Fab fragments for severe digitalis intoxication in children. N Engl J Med 1992; 326: 1739-44.
32. Wofford JL, Ettinger WH. Risk factors and manifestations of digoxin toxicity in the elderly. Am J Emerg Med 1991; 9: 11-5.
33. Ujhelyi MR, Robert S, Cummings DM, Colucci RD, Green PJ, Sailstad J, et al. Influence of digoxin immune Fab therapy and renal dysfunction on the disposition of total and free digoxin. Ann Intern Med 1993; 119: 273-7.
34. Ujhelyi MR, Robert S. Pharmacokinetic aspects of digoxinspecific Fab therapy in the management of digitalis toxicity. Clin Pharmacokinet 1995; 28: 483-93.
35. Kirkpatrick CH. Allergic histories and reactions of patients treated with digoxin immune Fab (ovine) antibody. The Digibind Study Advisory Panel. Am J Emerg Med 1991; 9: 7-10.
36. Bosse GM, Pope TM. Recurrent digoxin overdose and treatment with digoxin-specific Fab antibody fragments. J Emerg Med 1994; 12: 179-85.
37. Keyler DE, Salerno DM, Murakami MM, Ruth G, Pentel PR. Rapid administration of high-dose human antibody Fab fragments to dogs: Pharmacokinetics and toxicity. Fundam Appl Toxicol 1991; 17: 83-91.
38. Dally S, Alperovitch A, Lagier G, Bismuth C, Fournier E. Facteurs pronostiques de l'intoxication digitalique. Nouv Presse Med 1981; 10: 2257-60.